Protagonist Therapeutics ... (PTGX)
NASDAQ: PTGX
· Real-Time Price · USD
47.59
1.84 (4.02%)
At close: May 29, 2025, 3:59 PM
47.99
0.84%
After-hours: May 29, 2025, 06:58 PM EDT
4.02% (1D)
| Bid | 44 |
| Market Cap | 2.95B |
| Revenue (ttm) | 207.8M |
| Net Income (ttm) | 56.19M |
| EPS (ttm) | 0.78 |
| PE Ratio (ttm) | 61.01 |
| Forward PE | -89.25 |
| Analyst | Buy |
| Ask | 48.4 |
| Volume | 560,871 |
| Avg. Volume (20D) | 1,247,318 |
| Open | 45.89 |
| Previous Close | 45.75 |
| Day's Range | 45.43 - 47.65 |
| 52-Week Range | 27.00 - 60.60 |
| Beta | 2.64 |
About PTGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PTGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+45.89%
Protagonist Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
2 months ago
+2.42%
Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.
3 weeks ago · accessnewswire.com
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePositive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call ...
2 months ago · seekingalpha.com
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry ItProtagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotr...
